



05 APR 2005

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
P.O. Box 1450  
ALEXANDRIA, VA 22313-1450  
www.uspto.gov

Robert C. Faber  
Ostrolenk, Faber, Gerb & Soffen, LLP  
1180 Avenue of the Americas  
New York, NY 10036-8403

In re Application of  
DURAFFOURD, et al.  
Application No.: 10/502,237  
PCT No.: PCT/FR02/03089  
Int. Filing Date: 11 September 2002  
Priority Date: 11 September 2001  
Att. Docket No.: P/24-182  
For: METHOD FOR DETERMINING A PATIENT'S  
BIOLOGICAL STATE

DECISION ON PETITION

UNDER 37 CFR 1.137(b)

The petition to revive under 37 CFR 1.137(b) filed 22 July 2004 in the above-captioned application is hereby **GRANTED** as follows:

Applicant's statement that "The undersigned, attorney for the Applicant, has been advised by the Applicant and therefore is informed and believes that the entire delay in entering the national stage in the United States Patent and Trademark Office from the due date for entering the national phase in the United States until the date of this petition was unintentional by the Applicant" and the prompt filing of the petition satisfies the requirement of 37 CFR 1.137(b)(3).

A review of the application file reveals that applicant has now provided payment of the full, U.S. Basic National fee and the requirements of 37 CFR 1.137(b) have been satisfied. Therefore, the request to revive the application abandoned under 35 U.S.C. 371(d) is granted as to the National stage in the United States of America.

The application has an international filing date of 11 September 2002 under 35 U.S.C. 363 and will be given a date of **22 July 2004** under 35 U.S.C. 371(c)(1), (c)(2) and (c)(4).

This application is being returned to the United States Designated/Elected Office (DO/EO/US) for treatment in accordance with this decision.

Derek A. Putonen  
Attorney Advisor  
Office of PCT Legal Administration  
Tel: (571) 272-3294  
Fax: (571) 273-0459